Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases.
Donato CoscoFederica BrunoGermano CastelliRoberto PuleioSonia BonacciAntonio ProcopioDomenico BrittiMassimo FrestaFabrizio VitaleDonatella PaolinoPublished in: Macromolecular bioscience (2021)
Leishmaniasis is a human and animal disease endemic in tropical and subtropical areas treated by means of pentavalent antimony as first-line approach. Unfortunately, the formulations available on the market are characterized by significant side effects and a total remission of the disease is difficult to be obtained. The aim of this investigation is to describe the development and characterization of aqueous-core poly-l-lactide (PLA) nanocapsules containing glucantime (meglumine antimoniate, MA) with the aim of increasing the pharmacological efficacy of the active compound. The polymeric systems characterized by a mean diameter of ≈300 nm exert a great interaction with murine macrophages. MA-loaded PLA nanocapsules show a great antileishmanial activity on mice infected with Leishmania infantum with respect to the free drug, favoring a decrease of the administration times. The biodistribution profiles demonstrate a lower renal accumulation of MA after its nanoencapsulation and a significant increase of its plasmatic half-life. The parasite load evaluated by immunohistochemistry shows a significant decrease in liver, spleen, and kidneys when mice are treated with MA-loaded PLA nanocapsules especially after 45 days. The obtained results demonstrate the potential application of MA-loaded PLA nanocapsules as novel nanomedicine for the treatment of leishmaniasis.
Keyphrases
- drug delivery
- cancer therapy
- wound healing
- endothelial cells
- drug release
- high fat diet induced
- ionic liquid
- drug induced
- photodynamic therapy
- systemic lupus erythematosus
- newly diagnosed
- computed tomography
- adipose tissue
- pet imaging
- health insurance
- wild type
- optic nerve
- risk assessment
- metabolic syndrome
- disease activity
- electronic health record
- positron emission tomography
- toxoplasma gondii
- pet ct